Immunosuppressant – Pharmaports LLC

API Products

Immunosuppressant

Mycophenolate Mofetil HCI Mycophenolate Mofetil Rapamycin Tacrolimus Mycophenolate Sodium Tacrolimus SD20 Everolimus

Mycophenolate Mofetil HCI

Mycophenolate Mofetil HCI
Category	Immunosuppressant
CAS	116680-01-4
Specification	In-house
US DMF	24372
CEP/EDMF	N/A
GMP Certification	N/A
Inspection	N/A
Status	Commercial
Major Market & Regulation	USA, EU and Japan Market

Mycophenolate Mofetil

Mycophenolate Mofetil
Category	Immunosuppressive Agent
CAS	115007-34-6
Specification	EP/USP
US DMF	18494
CEP/EDMF	Canada, EMEA
GMP Certification	FDA
Inspection	FDA
Status	Commercial
Major Market & Regulation	USA, EU and Japan Market

Rapamycin

Rapamycin
Category	Immunosuppressive Agent
CAS	53123-88-9
Specification	In-house
US DMF	17399
CEP/EDMF	Canada, EMEA
GMP Certification	N/A
Inspection	N/A
Status	Commercial
Major Market & Regulation	USA, EU and Japan Market

Tacrolimus

Tacrolimus
Category	Immunosuppressive Agent
CAS	109581-93-3
Specification	In-house
US DMF	18985
CEP/EDMF	N/A
GMP Certification	FDA
Inspection	FDA and PMDA
Status	Commercial
Major Market & Regulation	USA, EU and Japan Market

Mycophenolate Sodium

Mycophenolate Sodium
Category	Immunosuppressive Agent
CAS	37415-62-6
Specification	In-house
US DMF	23435
CEP/EDMF	N/A
GMP Certification	N/A
Inspection	N/A
Status	Commercial
Major Market & Regulation	USA, EU and Japan Market

Tacrolimus SD20

Tacrolimus SD20
Category	Immunosuppressant
CAS	109581-93-3
Specification	In-house
US DMF	23213
CEP/EDMF	N/A
GMP Certification	N/A
Inspection	N/A
Status	Commercial
Major Market & Regulation	USA, EU and Japan Market

Everolimus

Everolimus
Category	Immunosuppressive Agent
CAS	9003-97-8
Specification	In-house
US DMF	26819/27216
CEP/EDMF	N/A
GMP Certification	N/A
Inspection	TFDA
Status	Commercial
Major Market & Regulation	USA, EU and Japan Market